Skip to main content
Erschienen in: World Journal of Urology 7/2016

02.11.2015 | Original Article

Elevated plasma aldosterone is an independent risk factor for erectile dysfunction in men

verfasst von: Fei Wu, Shanhua Mao, Tianfang Yu, Haowen Jiang, Qiang Ding, Gang Xu

Erschienen in: World Journal of Urology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Erectile dysfunction (ED) and cardiovascular disease (CVD) share a great number of common risk factors. There is growing evidence that aldosterone, an independent CVD risk factor, is associated with ED.

Aims

The purpose of this study was to determine the relationship between plasma aldosterone and erectile dysfunction.

Methods

This study recruited 287 participants, ranging from 18 to 84 years old; 217 were suffering from ED, diagnosed by the International Index of Erectile Function 5 (IIEF-5) scores. Based on IIEF-5 scores, patients were divided into one control group and three ED groups (mild ED; moderate ED; severe ED).

Main outcome measures

The differences in principal characteristics, blood routine, sexual hormone, adrenal hormone, thyroid hormone, renal function, liver function and blood lipid were compared between ED and control groups.

Results

Our study demonstrated that the difference of mean plasma aldosterone levels between ED group and the control group was statistically significant (P < 0.05). Stepwise logistic regression analysis of all the possible factors support the role of aldosterone as an independent risk factor for ED (OR 1.011; 95 % CI 1.003–1.018; P = 0.004). Similar statistical methods were applied to the comparison between moderate to severe ED group and control to mild ED group (OR 1.017; 95 % CI 1.009–1.024; P < 0.001). ROC curve and the area under the curve (0.718; 95 % CI 0.643–0.794; P < 0.001) were performed to assess the diagnostic effect and to compare the severity of risk with the known independent risk factors, such as age and cholesterol (0.704; 95 % CI 0.631–0.778; P < 0.001). When using a 374 pg/mL cut-off value from Youden index, the OR of ED group versus controls is 3.106 (95 % CI 1.458–6.617), while the OR of moderate to severe ED versus control and mild ED is 5.480 (95 % CI 3.108–9.662).

Conclusions

We determined that elevated plasma aldosterone concentration is an independent risk factor for ED. Our findings also indicate that the aldosterone, a well-recognized contributor to vascular injury, might be a potential bond between ED and CVD.
Literatur
1.
Zurück zum Zitat Shaeer O, Shaeer K (2012) The Global Online Sexuality Survey (GOSS): the United States of America in 2011. Chapter I: erectile dysfunction among English-speakers. J Sex Med 912:3018–3027CrossRef Shaeer O, Shaeer K (2012) The Global Online Sexuality Survey (GOSS): the United States of America in 2011. Chapter I: erectile dysfunction among English-speakers. J Sex Med 912:3018–3027CrossRef
2.
Zurück zum Zitat Hwang TI, Tsai TF, Lin YC et al (2010) A survey of erectile dysfunction in Taiwan: use of the erection hardness score and quality of erection questionnaire. J Sex Med 78:2817–2824CrossRef Hwang TI, Tsai TF, Lin YC et al (2010) A survey of erectile dysfunction in Taiwan: use of the erection hardness score and quality of erection questionnaire. J Sex Med 78:2817–2824CrossRef
3.
Zurück zum Zitat Gratzke C, Angulo J, Chitaley K et al (2010) Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 71(Pt 2):445–475CrossRef Gratzke C, Angulo J, Chitaley K et al (2010) Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 71(Pt 2):445–475CrossRef
4.
Zurück zum Zitat Dong JY, Zhang YH, Qin LQ (2011) Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 5813:1378–1385CrossRef Dong JY, Zhang YH, Qin LQ (2011) Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 5813:1378–1385CrossRef
5.
Zurück zum Zitat Gandaglia G, Briganti A, Jackson G et al (2014) A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol 655:968–978CrossRef Gandaglia G, Briganti A, Jackson G et al (2014) A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol 655:968–978CrossRef
6.
Zurück zum Zitat Graham J (2013) Erectile dysfunction and cardiovascular disease. Arab J Urol 113:212–216 Graham J (2013) Erectile dysfunction and cardiovascular disease. Arab J Urol 113:212–216
7.
Zurück zum Zitat Buvat J, Maggi M, Gooren L et al (2010) Endocrine aspects of male sexual dysfunctions. J Sex Med 74(Pt 2):1627–1656CrossRef Buvat J, Maggi M, Gooren L et al (2010) Endocrine aspects of male sexual dysfunctions. J Sex Med 74(Pt 2):1627–1656CrossRef
8.
Zurück zum Zitat De Rosa M, Zarrilli S, Vitale G et al (2004) Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 892:621–625CrossRef De Rosa M, Zarrilli S, Vitale G et al (2004) Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 892:621–625CrossRef
9.
Zurück zum Zitat Galdiero M, Pivonello R, Grasso LF et al (2012) Growth hormone, prolactin, and sexuality. J Endocrinol Invest 358:782–794CrossRef Galdiero M, Pivonello R, Grasso LF et al (2012) Growth hormone, prolactin, and sexuality. J Endocrinol Invest 358:782–794CrossRef
10.
Zurück zum Zitat Reiter WJ, Pycha A, Schatzl G et al (1999) Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology 533:590–594 (discussion 594–5) CrossRef Reiter WJ, Pycha A, Schatzl G et al (1999) Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. Urology 533:590–594 (discussion 594–5) CrossRef
11.
Zurück zum Zitat Morales A, Black A, Emerson L et al (2009) Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male 124:104–112CrossRef Morales A, Black A, Emerson L et al (2009) Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency. Aging Male 124:104–112CrossRef
12.
Zurück zum Zitat Papanicolaou DA, Yanovski JA, Cutler GB Jr et al (1998) A single midnight serum cortisol measurement distinguishes Cushing’s syndrome from pseudo-Cushing states. J Clin Endocrinol Metab 834:1163–1167 Papanicolaou DA, Yanovski JA, Cutler GB Jr et al (1998) A single midnight serum cortisol measurement distinguishes Cushing’s syndrome from pseudo-Cushing states. J Clin Endocrinol Metab 834:1163–1167
13.
Zurück zum Zitat Kalaitzidou I, Venetikou MS, Konstadinidis K et al (2014) Stress management and erectile dysfunction: a pilot comparative study. Andrologia 466:698–702CrossRef Kalaitzidou I, Venetikou MS, Konstadinidis K et al (2014) Stress management and erectile dysfunction: a pilot comparative study. Andrologia 466:698–702CrossRef
14.
Zurück zum Zitat Krassas GE, Tziomalos K, Papadopoulou F et al (2008) Erectile dysfunction in patients with hyper- and hypothyroidism: How common and should we treat? J Clin Endocrinol Metab 935:1815–1819CrossRef Krassas GE, Tziomalos K, Papadopoulou F et al (2008) Erectile dysfunction in patients with hyper- and hypothyroidism: How common and should we treat? J Clin Endocrinol Metab 935:1815–1819CrossRef
15.
Zurück zum Zitat Veronelli A, Masu A, Ranieri R et al (2006) Prevalence of erectile dysfunction in thyroid disorders: comparison with control subjects and with obese and diabetic patients. Int J Impot Res 181:111–114CrossRef Veronelli A, Masu A, Ranieri R et al (2006) Prevalence of erectile dysfunction in thyroid disorders: comparison with control subjects and with obese and diabetic patients. Int J Impot Res 181:111–114CrossRef
16.
Zurück zum Zitat Salonia A, Castagna G, Sacca A et al (2012) Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function-Erectile Function domain. J Sex Med 910:2708–2715CrossRef Salonia A, Castagna G, Sacca A et al (2012) Is erectile dysfunction a reliable proxy of general male health status? The case for the International Index of Erectile Function-Erectile Function domain. J Sex Med 910:2708–2715CrossRef
17.
Zurück zum Zitat Jackson G, Montorsi P, Adams MA et al (2010) Cardiovascular aspects of sexual medicine. J Sex Med 74(Pt 2):1608–1626CrossRef Jackson G, Montorsi P, Adams MA et al (2010) Cardiovascular aspects of sexual medicine. J Sex Med 74(Pt 2):1608–1626CrossRef
18.
Zurück zum Zitat Rossi G, Boscaro M, Ronconi V et al (2005) Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 163:104–107CrossRef Rossi G, Boscaro M, Ronconi V et al (2005) Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 163:104–107CrossRef
19.
Zurück zum Zitat Deo R, Yang W, Khan AM et al (2014) Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension 641:103–110CrossRef Deo R, Yang W, Khan AM et al (2014) Serum aldosterone and death, end-stage renal disease, and cardiovascular events in blacks and whites: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Hypertension 641:103–110CrossRef
20.
Zurück zum Zitat Funder JW (2007) The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs 73:151–157CrossRef Funder JW (2007) The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. Am J Cardiovasc Drugs 73:151–157CrossRef
21.
Zurück zum Zitat Kishimoto T, Fukawa T, Yamaguchi K et al (2013) Mineralocorticoid receptor expression in human penile corpus cavernosum. J Med Invest 601–2:21–26CrossRef Kishimoto T, Fukawa T, Yamaguchi K et al (2013) Mineralocorticoid receptor expression in human penile corpus cavernosum. J Med Invest 601–2:21–26CrossRef
22.
Zurück zum Zitat Muguruma H, Kawanishi Y, Sugiyama H et al (2008) Effect of aldosterone on isolated human penile corpus cavernosum tissue. BJU Int 1024:500–503CrossRef Muguruma H, Kawanishi Y, Sugiyama H et al (2008) Effect of aldosterone on isolated human penile corpus cavernosum tissue. BJU Int 1024:500–503CrossRef
23.
Zurück zum Zitat Rosen RC, Riley A, Wagner G et al (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 496:822–830CrossRef Rosen RC, Riley A, Wagner G et al (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 496:822–830CrossRef
24.
Zurück zum Zitat Giambene B, Sodi A, Sofi F et al (2009) Evaluation of traditional and emerging cardiovascular risk factors in patients with non-arteritic anterior ischemic optic neuropathy: a case-control study. Graefes Arch Clin Exp Ophthalmol 2475:693–697CrossRef Giambene B, Sodi A, Sofi F et al (2009) Evaluation of traditional and emerging cardiovascular risk factors in patients with non-arteritic anterior ischemic optic neuropathy: a case-control study. Graefes Arch Clin Exp Ophthalmol 2475:693–697CrossRef
25.
Zurück zum Zitat Ponholzer A, Temml C, Rauchenwald M et al (2006) Vascular risk factors and erectile dysfunction in a cohort of healthy men. Int J Impot Res 185:489–493CrossRef Ponholzer A, Temml C, Rauchenwald M et al (2006) Vascular risk factors and erectile dysfunction in a cohort of healthy men. Int J Impot Res 185:489–493CrossRef
26.
Zurück zum Zitat Lamounier-Zepter V, Ehrhart-Bornstein M (2006) Fat tissue metabolism and adrenal steroid secretion. Curr Hypertens Rep 81:30–34CrossRef Lamounier-Zepter V, Ehrhart-Bornstein M (2006) Fat tissue metabolism and adrenal steroid secretion. Curr Hypertens Rep 81:30–34CrossRef
27.
Zurück zum Zitat Marcus Y, Shefer G, Stern N (2013) Adipose tissue renin-angiotensin-aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol 3781(2):1–14CrossRef Marcus Y, Shefer G, Stern N (2013) Adipose tissue renin-angiotensin-aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol 3781(2):1–14CrossRef
28.
Zurück zum Zitat Feliciano Pereira P, Eloiza Priore S, Bressan J (2014) Aldosterone: A cardiometabolic risk hormone? Nutr Hosp 306:1191–1202 Feliciano Pereira P, Eloiza Priore S, Bressan J (2014) Aldosterone: A cardiometabolic risk hormone? Nutr Hosp 306:1191–1202
29.
Zurück zum Zitat Wada T, Miyashita Y, Sasaki M et al (2013) Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. Am J Physiol Endocrinol Metab 30511:E1415–E1425CrossRef Wada T, Miyashita Y, Sasaki M et al (2013) Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. Am J Physiol Endocrinol Metab 30511:E1415–E1425CrossRef
30.
Zurück zum Zitat Emanuele E, Geroldi D, Minoretti P et al (2005) Increased plasma aldosterone in patients with clinical depression. Arch Med Res 365:544–548CrossRef Emanuele E, Geroldi D, Minoretti P et al (2005) Increased plasma aldosterone in patients with clinical depression. Arch Med Res 365:544–548CrossRef
31.
Zurück zum Zitat Kubzansky LD, Adler GK (2010) Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease. Neurosci Biobehav Rev 341:80–86CrossRef Kubzansky LD, Adler GK (2010) Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease. Neurosci Biobehav Rev 341:80–86CrossRef
32.
Zurück zum Zitat Granata A, Tirabassi G, Pugni V et al (2013) Sexual dysfunctions in men affected by autoimmune Addison’s disease before and after short-term gluco- and mineralocorticoid replacement therapy. J Sex Med 108:2036–2043CrossRef Granata A, Tirabassi G, Pugni V et al (2013) Sexual dysfunctions in men affected by autoimmune Addison’s disease before and after short-term gluco- and mineralocorticoid replacement therapy. J Sex Med 108:2036–2043CrossRef
33.
Zurück zum Zitat Penson DF, Ng C, Rajfer J et al (1997) Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology 1389:3925–3932 Penson DF, Ng C, Rajfer J et al (1997) Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology 1389:3925–3932
34.
Zurück zum Zitat Balercia G, Boscaro M, Lombardo F et al (2007) Sexual symptoms in endocrine diseases: psychosomatic perspectives. Psychother Psychosom 763:134–140CrossRef Balercia G, Boscaro M, Lombardo F et al (2007) Sexual symptoms in endocrine diseases: psychosomatic perspectives. Psychother Psychosom 763:134–140CrossRef
35.
Zurück zum Zitat Burnett AL, Musicki B, Jin L et al (2006) Nitric oxide/redox-based signalling as a therapeutic target for penile disorders. Expert Opin Ther Targets 103:445–457CrossRef Burnett AL, Musicki B, Jin L et al (2006) Nitric oxide/redox-based signalling as a therapeutic target for penile disorders. Expert Opin Ther Targets 103:445–457CrossRef
36.
Zurück zum Zitat Jin L, Ying Z, Hilgers RH et al (2006) Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. J Pharmacol Exp Ther 3181:288–295CrossRef Jin L, Ying Z, Hilgers RH et al (2006) Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. J Pharmacol Exp Ther 3181:288–295CrossRef
37.
Zurück zum Zitat Caprio M, Mammi C, Jaffe IZ et al (2008) The mineralocorticoid receptor in endothelial physiology and disease: novel concepts in the understanding of erectile dysfunction. Curr Pharm Des 1435:3749–3757CrossRef Caprio M, Mammi C, Jaffe IZ et al (2008) The mineralocorticoid receptor in endothelial physiology and disease: novel concepts in the understanding of erectile dysfunction. Curr Pharm Des 1435:3749–3757CrossRef
38.
Zurück zum Zitat Jaffe IZ, Mendelsohn ME (2005) Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res 966:643–650CrossRef Jaffe IZ, Mendelsohn ME (2005) Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res 966:643–650CrossRef
39.
Zurück zum Zitat Caprio M, Newfell BG, la Sala A et al (2008) Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 10211:1359–1367CrossRef Caprio M, Newfell BG, la Sala A et al (2008) Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 10211:1359–1367CrossRef
40.
Zurück zum Zitat Farquharson CA, Struthers AD (2002) Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 1034:425–431CrossRef Farquharson CA, Struthers AD (2002) Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 1034:425–431CrossRef
41.
Zurück zum Zitat Macdonald JE, Kennedy N, Struthers AD (2004) Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 907:765–770CrossRef Macdonald JE, Kennedy N, Struthers AD (2004) Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 907:765–770CrossRef
42.
Zurück zum Zitat Leopold JA, Dam A, Maron BA et al (2007) Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 132:189–197CrossRef Leopold JA, Dam A, Maron BA et al (2007) Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 132:189–197CrossRef
43.
Zurück zum Zitat Suzuki J, Iwai M, Mogi M et al (2006) Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 264:917–921CrossRef Suzuki J, Iwai M, Mogi M et al (2006) Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 264:917–921CrossRef
44.
Zurück zum Zitat Bivalacqua TJ, Champion HC, Usta MF et al (2004) RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 10124:9121–9126CrossRef Bivalacqua TJ, Champion HC, Usta MF et al (2004) RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 10124:9121–9126CrossRef
45.
Zurück zum Zitat Chang S, Hypolite JA, Changolkar A et al (2003) Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res 151:53–62CrossRef Chang S, Hypolite JA, Changolkar A et al (2003) Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res 151:53–62CrossRef
46.
Zurück zum Zitat Tokuyama H, Wakino S, Hara Y et al (2012) Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury. Int J Obes (Lond) 368:1062–1071CrossRef Tokuyama H, Wakino S, Hara Y et al (2012) Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury. Int J Obes (Lond) 368:1062–1071CrossRef
47.
Zurück zum Zitat Iizuka K, Yoshii A, Samizo K et al (1999) A major role for the rho-associated coiled coil forming protein kinase in G-protein-mediated Ca2+ sensitization through inhibition of myosin phosphatase in rabbit trachea. Br J Pharmacol 1284:925–933CrossRef Iizuka K, Yoshii A, Samizo K et al (1999) A major role for the rho-associated coiled coil forming protein kinase in G-protein-mediated Ca2+ sensitization through inhibition of myosin phosphatase in rabbit trachea. Br J Pharmacol 1284:925–933CrossRef
48.
Zurück zum Zitat Chitaley K, Wingard CJ, Clinton Webb R et al (2001) Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 71:119–122CrossRef Chitaley K, Wingard CJ, Clinton Webb R et al (2001) Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 71:119–122CrossRef
49.
Zurück zum Zitat Sauzeau V, Le Jeune H, Cario-Toumaniantz C et al (2000) Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 27528:21722–21729CrossRef Sauzeau V, Le Jeune H, Cario-Toumaniantz C et al (2000) Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 27528:21722–21729CrossRef
50.
Zurück zum Zitat Sawada N, Itoh H, Yamashita J et al (2001) cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun 2803:798–805CrossRef Sawada N, Itoh H, Yamashita J et al (2001) cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun 2803:798–805CrossRef
51.
Zurück zum Zitat Nagata D, Takahashi M, Sawai K et al (2006) Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 481:165–171CrossRef Nagata D, Takahashi M, Sawai K et al (2006) Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 481:165–171CrossRef
Metadaten
Titel
Elevated plasma aldosterone is an independent risk factor for erectile dysfunction in men
verfasst von
Fei Wu
Shanhua Mao
Tianfang Yu
Haowen Jiang
Qiang Ding
Gang Xu
Publikationsdatum
02.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 7/2016
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-015-1723-0

Weitere Artikel der Ausgabe 7/2016

World Journal of Urology 7/2016 Zur Ausgabe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.